title: Consider rifampin BUT be cautious.
authors.forename: David
authors.initials: D
authors.lastname: Ashkin
authors.forename: Joanne
authors.initials: J
authors.lastname: Julien
authors.forename: Michael
authors.initials: M
authors.lastname: Lauzardo
authors.forename: Elena
authors.initials: E
authors.lastname: Hollender
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage / Q000009:adverse effects; D015337:Multicenter Studies as Topic; D010349:Patient Compliance; D016032:Randomized Controlled Trials as Topic; D012293:Rifampin / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin